AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Tg Therapeutics MACD Death Cross and Bollinger Bands Narrowing on 15min chart
ByAinvest
Thursday, Sep 18, 2025 3:47 pm ET1min read
Tg Therapeutics' 15-minute chart has exhibited a MACD Death Cross and Bollinger Bands Narrowing at 09/18/2025 15:45. This indicates that the stock price has the potential to continue falling, with a decreasing magnitude of price fluctuations.
B. Riley Securities has maintained its Buy rating for TG Therapeutics Inc. (TGTX) and raised the price target from $53.00 to $55.00, reflecting a 3.77% increase as of September 17, 2025. The analyst responsible for this update, Mayank Mamtani, suggests that this adjustment aligns with recent market evaluations and strategic company developments. TG Therapeutics continues to be seen favorably within the market, as indicated by the maintained Buy rating.TG Therapeutics Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). Additionally, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials.
According to Wall Street analysts, the average one-year price target for TG Therapeutics Inc. is $42.00, with a high estimate of $55.00 and a low estimate of $11.00. The average target implies an upside of 29.91% from the current price of $32.33. Based on the consensus recommendation from 9 brokerage firms, the average brokerage recommendation is currently 2.2, indicating an "Outperform" status.
B. Riley Securities' updated price target of $55.00 suggests a significant upside potential for TG Therapeutics Inc. However, recent technical indicators, such as the MACD Death Cross and Bollinger Bands Narrowing observed on September 18, 2025, at 15:45, indicate a potential for continued stock price decline with decreasing magnitude of price fluctuations [1].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet